Tarsus Pharmaceuticals Inc. (TARS), a biopharmaceutical company developing therapeutic candidates to address highly prevalent diseases with limited treatment options, has two clinical trial catalysts to watch.
Topline data from the company's Galatea study and Carpo study are due this quarter.
Galatea
Galatea is a phase IIa clinical trial evaluating the company's investigational drug TP-04 in the treatment of papulopustular rosacea.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.